Stryker Corporation. (NYSE:SYK) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET
Company Participants
Kevin Lobo - Chair and Chief Executive Officer
Jason Beach - Vice President, Finance and Investor Relations
Glenn Boehnlein - Vice President, Chief Financial Officer
Conference Call Participants
Robert Marcus - JPMorgan
Lawrence Biegelsen - Wells Fargo Securities
Joanne Wuensch - Citi
Ryan Zimmerman - BTIG
Travis Steed - Bank of America
Matthew O’Brien - Piper Sandler Companies
Vijay Kumar - Evercore ISI
Matthew Miksic - Barclays
Steven Litchman - Oppenheimer & Co
David Roman - Goldman Sachs
Christopher Pasquale - Nephron Research
Jason Wittes - Roth MKM
Michael Matson - Needham & Company
Danielle Antalffy - UBS Equities
Richard Newitter - Truist Securities
Matthew Taylor - Jefferies
Jeffrey Johnson - Robert W. Baird & Co
Caitlin Cronin - Canaccord Genuity
Eric Anderson - TD Cowen
Operator
Welcome to the Third Quarter 2024 Stryker Earning Call. My name is Luke, and I'm your operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.
Kevin Lobo
Welcome to Stryker's third quarter earnings call. Joining me today are Glenn Boehnlein, Stryker’s CFO, and Jason Beach, Vice President of Finance and Investor Relations.
For today's call, I'll provide opening comments followed by Jason with the trends we saw during the quarter and some product updates. Glenn will then provide additional details regarding our quarterly results before opening the call to Q&A.
In the third quarter we delivered robust organic sales growth of 11.5%. Our performance included strong double-digit growth within MedSurg and Neurotechnology and nearly 10% growth in Orthopedics and Spine. This broad performance reflects healthy demand across our diverse product portfolio and our team's steadfast commercial execution. Our strong results reflect double-digit organic growth from our medical, neuro cranial endoscopy, trauma and extremities, hips and knees businesses.